Missouri Trust & Investment Co Purchases 2,012 Shares of Merck & Co., Inc. (NYSE:MRK)

Missouri Trust & Investment Co grew its position in Merck & Co., Inc. (NYSE:MRKFree Report) by 24.1% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 10,372 shares of the company’s stock after buying an additional 2,012 shares during the period. Missouri Trust & Investment Co’s holdings in Merck & Co., Inc. were worth $1,131,000 at the end of the most recent quarter.

Several other large investors have also recently modified their holdings of the company. Wellington Management Group LLP increased its position in Merck & Co., Inc. by 6.7% during the 3rd quarter. Wellington Management Group LLP now owns 82,442,666 shares of the company’s stock valued at $8,487,472,000 after buying an additional 5,196,914 shares in the last quarter. Charles Schwab Investment Management Inc. increased its holdings in shares of Merck & Co., Inc. by 14.8% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 36,682,866 shares of the company’s stock valued at $3,966,029,000 after acquiring an additional 4,731,152 shares in the last quarter. International Assets Investment Management LLC raised its position in shares of Merck & Co., Inc. by 10,221.4% in the 4th quarter. International Assets Investment Management LLC now owns 2,375,269 shares of the company’s stock valued at $258,952,000 after purchasing an additional 2,352,256 shares during the last quarter. AEGON ASSET MANAGEMENT UK Plc purchased a new position in shares of Merck & Co., Inc. in the 4th quarter valued at approximately $187,042,000. Finally, Northern Trust Corp boosted its stake in Merck & Co., Inc. by 4.1% in the 3rd quarter. Northern Trust Corp now owns 29,859,623 shares of the company’s stock worth $3,074,048,000 after purchasing an additional 1,186,842 shares in the last quarter. Institutional investors own 76.07% of the company’s stock.

Merck & Co., Inc. Price Performance

MRK traded up $0.31 during trading on Friday, hitting $131.19. The company’s stock had a trading volume of 8,281,595 shares, compared to its average volume of 7,287,899. The firm has a market capitalization of $332.28 billion, a price-to-earnings ratio of 145.77, a P/E/G ratio of 1.68 and a beta of 0.39. Merck & Co., Inc. has a twelve month low of $99.14 and a twelve month high of $133.10. The business’s fifty day simple moving average is $127.27 and its 200 day simple moving average is $118.73. The company has a current ratio of 1.25, a quick ratio of 0.99 and a debt-to-equity ratio of 0.77.

Merck & Co., Inc. (NYSE:MRKGet Free Report) last posted its quarterly earnings data on Thursday, April 25th. The company reported $2.07 earnings per share for the quarter, topping analysts’ consensus estimates of $1.94 by $0.13. The company had revenue of $15.78 billion during the quarter, compared to analysts’ expectations of $15.21 billion. Merck & Co., Inc. had a net margin of 3.76% and a return on equity of 14.05%. The firm’s revenue for the quarter was up 8.9% on a year-over-year basis. During the same period in the prior year, the business posted $1.40 earnings per share. On average, equities research analysts forecast that Merck & Co., Inc. will post 8.69 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

MRK has been the subject of a number of research analyst reports. StockNews.com raised shares of Merck & Co., Inc. from a “buy” rating to a “strong-buy” rating in a report on Friday, February 2nd. TheStreet downgraded Merck & Co., Inc. from a “b+” rating to a “c+” rating in a research note on Monday, March 4th. Barclays lifted their target price on Merck & Co., Inc. from $135.00 to $145.00 and gave the stock an “overweight” rating in a report on Friday, February 2nd. Truist Financial increased their price target on shares of Merck & Co., Inc. from $142.00 to $143.00 and gave the stock a “buy” rating in a report on Friday, April 26th. Finally, Societe Generale cut shares of Merck & Co., Inc. from a “hold” rating to a “sell” rating and set a $104.00 price objective for the company. in a research note on Monday, March 11th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $131.33.

Read Our Latest Stock Report on Merck & Co., Inc.

Merck & Co., Inc. Profile

(Free Report)

Merck & Co, Inc operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names.

Featured Articles

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.